02220nas a2200253 4500000000100000008004100001260001200042653002200054653001700076653001400093653002300107653002000130653001900150100001400169700001400183700001500197700001300212700001200225245013900237856004800376490000700424520152100431022001401952 2019 d c12/201910aBiomphalaria spp.10aBulinus spp.10acercariae10aSub-Saharan Africa10aschistosomiasis10aClimate change1 aAdekiya T1 aAruleba R1 aOyinloye B1 aOkosun K1 aKappo A00aThe Effect of Climate Change and the Snail-Schistosome Cycle in Transmission and Bio-Control of Schistosomiasis in Sub-Saharan Africa. uhttps://www.mdpi.com/1660-4601/17/1/181/htm0 v173 a
In the next century, global warming, due to changes in climatic factors, is expected to have an enormous influence on the interactions between pathogens and their hosts. Over the years, the rate at which vector-borne diseases and their transmission dynamics modify and develop has been shown to be highly dependent to a certain extent on changes in temperature and geographical distribution. Schistosomiasis has been recognized as a tropical and neglected vector-borne disease whose rate of infection has been predicted to be elevated worldwide, especially in sub-Saharan Africa; the region currently with the highest proportion of people at risk, due to changes in climate. This review not only suggests the need to develop an efficient and effective model that will predict spp. population dynamics but seeks to evaluate the effectiveness of several current control strategies. The design of a framework model to predict and accommodate the future incidence of schistosomiasis in human population dynamics in sub-Saharan Africa is proposed. The impact of climate change on schistosomiasis transmission as well as the distribution of several freshwater snails responsible for the transmission of parasites in the region is also reviewed. Lastly, this article advocates for modelling several control mechanisms for schistosomiasis in sub-Saharan Africa so as to tackle the re-infection of the disease, even after treating infected people with praziquantel, the first-line treatment drug for schistosomiasis.
a1660-4601